|
KMID : 0939920200520010277
|
|
대한암학회지
2020 Volume.52 No. 1 p.277 ~ p.283
|
|
|
Clinical Characteristics of Clear Cell Ovarian Cancer: A Retrospective Multicenter Experience of 308 Patients in South Korea
|
|
Lee Hee-Yeon
Hong Ji-Hyung
Byun Jae-Ho
Kim Hee-Jun
Baek Sun-Kyung
Kim Jin-Young
Kim Ki-Hyang
Yun Ji-Na
Kim Jung-A
Park Kwon-Oh
Lee Hyo-Jin
Lee Jung-Lim
Won Young-Woong
Kim Il-Hwan
Bae Woo-Kyun
Park Kyong-Hwa
Sun Der-Sheng
Lee Sue-E
Lee Min-Young
Lee Guk-Jin
Hong Sook-Hee
Jung Yun-Hwa
An Ho-Jung
|
|
|
Abstract
|
|
|
Purpose: The purpose of this study was to evaluate clinical characteristics and treatment pattern of ovarian clear cell carcinoma (OCCC) in Korea and the role of adjuvant chemotherapy in early-stage.
Materials and Methods: Medical records of 308 cases of from 21 institutions were reviewed and data including age, performance status, endometriosis, thromboembolism, stage, cancer antigen 125, treatment, recurrence, and death were collected.
Results: Regarding stage of OCCC, it was stage I in 194 (63.6%), stage II in 34 (11.1%), stage III in 66 (21.6%), and stage IV in 11 (3.6%) patients. All patients underwent surgery. Optimal surgery (residual disease ≤ 1 cm) was achieved in 89.3%. Majority of patients (80.5%) received postoperative chemotherapy. The most common regimen was taxane-platinum combination (96%). Median relapse-free survival (RFS) was 138.5 months for stage I, 33.4 for stage II, 19.3 for stage III, and 9.7 for stage IV. Median overall survival (OS) were not reached, 112.4, 48.7, and 18.3 months for stage I, II, III, and IV, respectively. Early-stage (stage I), endometriosis, and optimal debulking were identified as favorable prognostic factors for RFS. Early-stage and optimal debulking were also favorable prognostic factors for OS. Majority of patients with early-stage received adjuvant chemotherapy. However, additional survival benefit was not found in terms of recurrence.
Conclusion: Majority of patients had early-stage and received postoperative chemotherapy regardless of stage. Early-stage and optimal debulking were identified as favorable prognostic factors. In stage IA or IB, adding adjuvant chemotherapy did not show difference in survival. Further study focusing on OCCC is required.
|
|
|
KEYWORD
|
|
|
Ovarian epithelial carcinoma, Clear cell adenocarcinoma, Korea, Adjuvant chemotherapy
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
    
|
|